Last $17.37 USD
Change Today -0.85 / -4.67%
Volume 226.9K
PRTA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

prothena corp plc (PRTA) Snapshot

Open
$18.21
Previous Close
$18.22
Day High
$18.21
Day Low
$17.26
52 Week High
03/20/14 - $49.24
52 Week Low
08/12/13 - $15.00
Market Cap
463.0M
Average Volume 10 Days
260.6K
EPS TTM
$-0.93
Shares Outstanding
26.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROTHENA CORP PLC (PRTA)

Related News

No related news articles were found.

prothena corp plc (PRTA) Related Businessweek News

No Related Businessweek News Found

prothena corp plc (PRTA) Details

Prothena Corporation plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel antibodies for the treatment of various diseases associated with protein misfolding or cell adhesion. Its product pipeline includes NEOD001, a product candidate in Phase 1 clinical trial to target AL and AA forms of amyloidosis; PRX002 for the treatment of Parkinson’s disease and related synucleinopathies; and PRX003 for the treatment of inflammatory disease and metastatic cancers. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dublin, Ireland.

39 Employees
Last Reported Date: 03/7/14
Founded in 2012

prothena corp plc (PRTA) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $462.1K
Chief Financial Officer
Total Annual Compensation: $278.8K
Chief Scientific Officer and Head of Research...
Total Annual Compensation: $349.2K
Chief Business Officer
Total Annual Compensation: $265.3K
Compensation as of Fiscal Year 2013.

prothena corp plc (PRTA) Key Developments

Prothena Corporation plc Presents at ROTH Healthcare Corporate Access Day - London, Jun-24-2014

Prothena Corporation plc Presents at ROTH Healthcare Corporate Access Day - London, Jun-24-2014 . Venue: The Dorchester, 3 Tilney Street, London, W1K 1BJ, United Kingdom.

Prothena Corporation plc Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 08:00 AM

Prothena Corporation plc Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 08:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Dale B. Schenk, Chief Executive Officer, President and Director.

Prothena Corporation plc Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Reaffirms Earnings Guidance for the Year 2013

Prothena Corporation plc reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported a net income of $17.9 million as compared to a net loss of $9.0 million for the first quarter of 2013. Net income per share was $0.78 on a diluted basis as compared to a net loss per share of $0.51 for the first quarter of 2013. Revenue was $32.2 million compared with $0.171 million a year ago. The increase was primarily due to $32.1 million in collaboration revenue recognized in relation to the PRX002 collaboration with Roche in the current quarter. Income from operations was $18.0 million compared with loss from operations of $8.967 million a year ago. Income before income taxes was $18.0 million compared with loss before income taxes of $8.945 million a year ago. The company expects net cash burn of $7 to $12 million for 2014, ending the year with approximately $167 million in cash (mid-point). The 2014 net cash burn is primarily driven by an estimated net loss of $13 to $18 million, which includes an estimated $6 million of non-cash share-based compensation expense.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRTA:US $17.37 USD -0.85

PRTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRTA.
View Industry Companies
 

Industry Analysis

PRTA

Industry Average

Valuation PRTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.2x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTHENA CORP PLC, please visit www.prothena.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.